Search - tctmd.com

Displaying 1 - 20 of 31

Sort: Relevancy | Date

Tailored Testing and Care Ease Angina for MINOCA Patients: PROMISE

News Conference News TCT 2025

Tailored Testing and Care Ease Angina for MINOCA Patients: PROMISE

October 28, 2025

MAPLE-HCM Is a Win, ODYSSEY-HCM Isn’t: Obstructive vs Nonobstructive Divide

News Conference News ESC 2025

MAPLE-HCM Is a Win, ODYSSEY-HCM Isn’t: Obstructive vs Nonobstructive Divide

August 30, 2025

WARRIOR: No Clear Answers on How to Best Treat INOCA

News Conference News ACC 2025

WARRIOR: No Clear Answers on How to Best Treat INOCA

Yael L. Maxwell

March 29, 2025

Indian Patients Do Well on Dual-Combination Pills for Hypertension: TOPSPIN

News Conference News AHA 2024

Indian Patients Do Well on Dual-Combination Pills for Hypertension: TOPSPIN

November 22, 2024

ESC’s 2024 CCS Guidelines Embrace New Data, Smooth Old Tensions

News Conference News ESC 2024

ESC’s 2024 CCS Guidelines Embrace New Data, Smooth Old Tensions

Michael O'Riordan

September 17, 2024

Go Beyond Angiography in CCS to Pinpoint the Problem, Urges AID-ANGIO

News Conference News EuroPCR 2024

Go Beyond Angiography in CCS to Pinpoint the Problem, Urges AID-ANGIO

May 14, 2024

SEQUOIA-HCM: Aficamten Boosts Exercise Capacity in Obstructive HCM

News Conference News ESC Heart Failure 2024

SEQUOIA-HCM: Aficamten Boosts Exercise Capacity in Obstructive HCM

Michael O'Riordan

May 13, 2024

IMPROVE-HCM: Ninerafaxstat May Fill a Niche in Nonobstructive HCM

News Conference News ACC 2024

IMPROVE-HCM: Ninerafaxstat May Fill a Niche in Nonobstructive HCM

April 15, 2024

Etripamil Nasal Spray in Paroxysmal SVT Speeds Conversion to Sinus Rhythm: RAPID

News Conference News AHA 2022

Etripamil Nasal Spray in Paroxysmal SVT Speeds Conversion to Sinus Rhythm: RAPID

November 07, 2022

Big Drops in Blood Pressure With Baxdrostat: BrigHTN Phase II Study

News Conference News AHA 2022

Big Drops in Blood Pressure With Baxdrostat: BrigHTN Phase II Study

Michael O'Riordan

November 07, 2022

Aficamten Safe, Effective for Up to 6 months in Obstructive HCM: REDWOOD-HCM OLE

News Conference News ESC Heart Failure 2022

Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE

May 31, 2022

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

News Conference News ACC 2022

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

April 03, 2022

In ANOCA, Diltiazem Fails to Improve Vasomotor Function: EDIT-CMD

News Conference News ACC 2022

In ANOCA, Diltiazem Fails to Improve Vasomotor Function: EDIT-CMD

April 02, 2022

Mavacamten Slashes Need for Septal Reduction in Obstructive HCM: VALOR-HCM

News Conference News ACC 2022

Mavacamten Slashes Need for Septal Reduction in Obstructive HCM: VALOR-HCM

Yael L. Maxwell

April 02, 2022

Spinal Cord Stimulation Reduces Post-CABG AF: Pilot Study

News Conference News HRS 2021

Spinal Cord Stimulation Reduces Post-CABG AF: Pilot Study

Michael O'Riordan

July 30, 2021

‘Enormous’ QoL Improvements With Mavacamten in HCM

News Conference News ACC 2021

‘Enormous’ QoL Improvements With Mavacamten in HCM

May 15, 2021

Insights From a Deep Dive Into CV Risk Among Hospitalized COVID-19 Patients

News Conference News ESC 2020

Insights From a Deep Dive Into CV Risk Among Hospitalized COVID-19 Patients

September 04, 2020

Antihypertensives Cut CV Events Across BP Levels, Regardless of Prior CVD: BPLTTC

News Conference News ESC 2020

Antihypertensives Cut CV Events Across BP Levels, Regardless of Prior CVD: BPLTTC

August 31, 2020

EXPLORER-HCM: Mavacamten Improves Exercise Capacity and Functional Class

News Conference News ESC 2020

EXPLORER-HCM: Mavacamten Improves Exercise Capacity and Functional Class

Michael O'Riordan

August 29, 2020

Ischemia Burden Not Linked to Angina in Nonobstructive CAD: CIAO

News Conference News ACC 2020

Ischemia Burden Not Linked to Angina in Nonobstructive CAD: CIAO

Michael O'Riordan

March 31, 2020

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.